Skip to main content

-

FJCI-2014-22983

•
Funding agency name Ministerio de Ciencia e Innovación
Funding agency acronym MICINN
Program Programa Estatal de Promoción del Talento y su Empleabilidad en I+D+i
Subprogram Subprograma Estatal de Formación
Call Juan de la Cierva Formación
Call year 2014
State Plan 2013-2016 Plan Estatal de Investigación Científica y Técnica y de Innovación
Management unit Secretaría de Estado de Educación, Formación Profesional y Universidades
Beneficiary centre INSTITUT DE RECERCA CONTRA LA LEUCEMIA JOSEP CARRERAS

Resultados relacionados

Resultados totales (Incluyendo duplicados): 2
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Polycomb protein RING1A limits hematopoietic differentiation in myelodysplastic syndromes

  • Palau de Miguel, Anna|||0000-0003-2131-1265
  • Garz, Anne-Kathrin
  • Diesch, Jeannine|||0000-0002-4667-3468
  • Zwick, Anabel
  • Malinverni, Roberto|||0000-0002-0113-3417
  • Valero, Vanesa
  • Lappin, Katrina
  • Casquero, Raquel
  • Lennartsson, Andreas
  • Zuber, Johannes|||0000-0001-8810-6835
  • Navarro, Tomàs
  • Mills, Ken I.
  • Götze, Katharina S.|||0000-0002-6276-8002
  • Buschbeck, Marcus|||0000-0002-3218-4567
Genetic lesions affecting epigenetic regulators are frequent in myelodysplastic syndromes (MDS). Polycomb proteins are key epigenetic regulators of differentiation and stemness that act as two multimeric complexes termed polycomb repressive complexes 1 and 2, PRC1 and PRC2, respectively. While components and regulators of PRC2 such as ASXL1 and EZH2 are frequently mutated in MDS and AML, little is known about the role of PRC1. To analyze the role of PRC1, we have taken a functional approach testing PRC1 components in loss- and gain-of-function experiments that we found overexpressed in advanced MDS patients or dynamically expressed during normal hematopoiesis. This approach allowed us to identify the enzymatically active component RING1A as the key PRC1 component in hematopoietic stem cells and MDS. Specifically, we found that RING1A is expressed in CD34 + bone marrow progenitor cells and further overexpressed in high-risk MDS patients. Knockdown of RING1A in an MDS-derived AML cell line facilitated spontaneous and retinoic acid-induced differentiation. Similarly, inactivation of RING1A in primary CD34 + cells augmented erythroid differentiation. Treatment with a small compound RING1 inhibitor reduced the colony forming capacity of CD34 + cells from MDS patients and healthy controls. In MDS patients higher RING1A expression associated with an increased number of dysplastic lineages and blasts. Our data suggests that RING1A is deregulated in MDS and plays a role in the erythroid development defect.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Inhibition of CBP synergizes with the RNA-dependent mechanisms of Azacitidine by limiting protein synthesis

  • Diesch, Jeannine|||0000-0002-4667-3468
  • Le Pannérer, Marguerite Marie|||0000-0002-5779-8805
  • Winkler, René|||0000-0002-7570-0242
  • Casquero, Raquel
  • Muhar, Matthias|||0000-0002-3018-9698
  • van der Garde, Mark
  • Maher, Michael|||0000-0002-4956-7185
  • Martínez Herráez, Carolina|||0000-0003-4711-7225
  • Bech-Serra, Joan-Josep|||0000-0003-3486-781X
  • Fellner, Michaela
  • Rathert, Philipp|||0000-0003-1477-136X
  • Brooks, Nigel
  • Zamora, Lurdes|||0000-0003-1713-7110
  • Gentilella, Antonio|||0000-0002-6830-2086
  • De La Torre Gómez, Gisela Carolina|||0000-0001-9363-291X
  • Zuber, Johannes|||0000-0001-8810-6835
  • Götze, Katharina S.|||0000-0002-6276-8002
  • Buschbeck, Marcus|||0000-0002-3218-4567
The nucleotide analogue azacitidine (AZA) is currently the best treatment option for patients with high-risk myelodysplastic syndromes (MDS). However, only half of treated patients respond and of these almost all eventually relapse. New treatment options are urgently needed to improve the clinical management of these patients. Here, we perform a loss-of-function shRNA screen and identify the histone acetyl transferase and transcriptional co-activator, CREB binding protein (CBP), as a major regulator of AZA sensitivity. Compounds inhibiting the activity of CBP and the closely related p300 synergistically reduce viability of MDS-derived AML cell lines when combined with AZA. Importantly, this effect is specific for the RNA-dependent functions of AZA and not observed with the related compound decitabine that is only incorporated into DNA. The identification of immediate target genes leads us to the unexpected finding that the effect of CBP/p300 inhibition is mediated by globally down regulating protein synthesis.